Ingredient name record

Azelaic Acid

Korean search label: 아젤라익애씨드

Evidence at a glance

2official function labelsIngredient context 2selected human studiesNot a full review

0selected legal receiptsNot a compliance verdict

Evidence coverage, not an efficacy or safety score.

Identity & coverage details

Official CosIng inventory context recorded; chemical identity and the complete current regulatory profile remain unverified; selected human studies available.

Recorded presence is not a safety rating, recommended dose or benefit claim.

Identity and formulation context

Names are indexed using case and whitespace normalization. Botanical, chemical and marketing identities have not been independently equated.

These are drug-treatment studies in melasma or rosacea. Concentrations and schedules describe experiments, not cosmetic recommendations. No transfer to potassium azeloyl diglycinate or a finished Treatfolio product is established.

Discovery spellings and aliases

azelaic · azelaic acid · azelaic acid 10% · 아젤라산 · 아젤라익 · 아젤라익 애씨드 · 아젤라익애씨드

Search-only metadata; an alias is not proof of chemical equivalence.

Functions listed by CosIng

BUFFERINGFRAGRANCE

Inventory functions describe the ingredient entry, not a finished product’s effects.

How this inventory match is used

The European Commission’s CosIng inventory is informational. An entry is not permission to use an ingredient or a safety assessment. Listed functions describe the inventory entry; they do not establish a finished product’s effects. The match uses the exact ingredient name, with case and whitespace normalization.

AZELAIC ACID · Inventory identifiers

Inventory record: 74538 · Active
CAS identifiers in this entry: 123-99-9
EC identifiers in this entry: 204-669-1

Checked 2026-10-02 · Read the official CosIng entry

Human study context

Primary publications checked 2026-10-02. These are selected studies, not a systematic review, safety rating or instructions for using a product.

The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream

1991 · Original abstract reviewed

Material tested: 20% azelaic acid cream, compared with 4% hydroquinone cream; both accompanied by broad-spectrum sunscreen.
Study design: Double-blind active-comparator study.
Participants: 329 women with melasma.
Concentration and schedule in the study: 24 weeks; application frequency is not given in the abstract.
What the authors reported: The azelaic-acid group had good or excellent overall ratings in 65% of cases. Overall rating, lesion-size reduction and pigmentation changes did not differ significantly between groups.

What this does not establish

Concurrent sunscreen and the active comparator prevent isolation against an untreated control.
This was disease treatment with 20% cream, not a test of cosmetic serums or azelaic-acid derivatives.
No observed severe reactions in this study does not establish universal safety.

Read the original publication

A phase 3 randomized, double-blind, vehicle-controlled trial of azelaic acid foam 15% in the treatment of papulopustular rosacea

2015 · Original abstract reviewed

Material tested: 15% azelaic acid foam compared with foam vehicle.
Study design: Randomized, double-blind, multicenter phase 3 vehicle-controlled trial.
Participants: Patients with papulopustular rosacea; sample size is not stated in the abstract.
Concentration and schedule in the study: Twice-daily study application; treatment duration is not stated in the abstract.
What the authors reported: Investigator-rated treatment success and inflammatory-lesion reduction were greater with the active foam than vehicle. Reported drug-related adverse events were mainly local skin reactions of mild-to-moderate severity.

What this does not establish

A medicinal foam for diagnosed rosacea is not interchangeable with a cosmetic serum.
The abstract omits sample size and duration; the full protocol was not reviewed.

Read the original publication

Still unverified

This is a selected partial literature record, not a systematic review or a complete scientific profile.
Cosmetic functions and jurisdiction-specific restrictions are not established by these research abstracts.
Study preparations have not been matched to any Treatfolio product, batch, market or concentration.
Chemical identity, the complete current regulatory profile and finished-product effects remain unverified.